Home Newsfeeds JonesTrading Downgrades Concert Pharma to Hold

JonesTrading Downgrades Concert Pharma to Hold

JonesTrading analyst Sean Kim downgrades Concert Pharma (NASDAQ:CNCE) from Buy to Hold.

byBenzinga Newsdesk

January 20, 2023

1 minute read

JonesTrading analyst Sean Kim downgrades Concert Pharma (NASDAQ:CNCE) from Buy to Hold.

B of A Securities Downgrades Olaplex Hldgs to Underperform, Lowers Price Target to $5

By Benzinga Newsdesk

October 19, 2:09 PM

B of A Securities analyst Jonathan Keypour downgrades Olaplex Hldgs (NASDAQ:OLPX) from Buy to Underperform and lowers the price target from $15 to $5.

OLPX

Dupixent Application For Treatment Of Chronic Spontaneous Urticaria In Adults And Adolescents Accepted For FDA Review

By Happy Mohamed

March 7, 2:19 AM

Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review More than 300,000 people in the

REGN

General Electric Offloads $2B Stake In GE HealthCare

By Shivani Kumaresan

June 6, 7:26 AM

General Electric Co (NYSE: GE) is offering 25 million shares in GE HealthCare Technologies Inc (NASDAQ:GEHC). The proceeds from the offering are expected to…

‘Full Stream Ahead’: BofA Hits The Play Button On Netflix Stock Expecting A Rerun Of Higher Share Prices

By Adam Eckert

November 15, 4:47 PM

BofA has stopped flipping through channels and tuned into Netflix Inc (NASDAQ: NFLX), anticipating a rerun of $370 per share.

NFLX

JonesTrading Downgrades Concert Pharma to Hold

Related Posts

B of A Securities Downgrades Olaplex Hldgs to Underperform, Lowers Price Target to $5

Dupixent Application For Treatment Of Chronic Spontaneous Urticaria In Adults And Adolescents Accepted For FDA Review

General Electric Offloads $2B Stake In GE HealthCare

‘Full Stream Ahead’: BofA Hits The Play Button On Netflix Stock Expecting A Rerun Of Higher Share Prices